| My Account | Subscribe | Contact Us | Donate |
Home
- The Edmonton Protocol and Me
- Olympia Dukakis and Her Husband Tackle Type 2
- Surfing with Type 1
- Behind the Wheel, But Still in Control
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
If you are a physician, educator and medical professional who focus on the treatment of diabetes, then this is the must have resource for you.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
You can cancel your newsletter subscription at anytime by clicking "Unsubscribe" on the bottom of any newsletter you receive
Then enter your new email address in the above form and click "Subscribe"
Latest Weight Loss Articles
Contrave deals with two issues, including the reward system in the brain that controls food preference and food cravings.
Investigational Weight Loss Drug Discussed at Obesity Society Annual Meeting
Orexigen Therapeutics has announced that the investigational weight loss drug Contrave (naltrexone SR/bupropion SR) reduced the prevalence of metabolic syndrome, which is associated with an increased risk of diabetes and heart disease, by 50 percent.
Contrave is a weight loss medication that works in two places in the central nervous system. It works in the hypothalmus which controls the balance of food intake and metabolism. Contrave also works to address a second site, the reward system in the brain that controls food preference and food cravings.
According to a press release from the recent annual Obesity Society Scientific Meeting in Phoenix, Arizona, in clinical trials, Contrave showed a significant weight loss over one year of treatment (approximately 8% to 10.7% in patients completing 48 weeks of therapy) by reducing appetite, increasing metabolism, and by changing the body's natural tendency to slow down the weight loss process. The developers expect to receive data from the first Contrave Phase 3 trials in January of 2009 and the remaining three trials by mid-next year.
Contrave is currently in Phase 3 clinical trials and in line for a late 2009 New Drug Application (NDA) submission to the FDA.
Further information can be found at Orexigen.com.
Source: The Obesity Society
Categories: Diets, Research, Type 2 Issues, Weight Loss
Facebook
MySpace 
Digg
You May Also Be Interested In...
Click Here To View Or Post Comments
Oct 13, 2008 -
Email to a Friend
Send a link to this page to your friends and colleagues.